Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mylan, Theravance to partner on nebulized COPD drug

This article was originally published in Scrip

Executive Summary

Mylan will spend $45m up front and pay up to $220m in milestone fees plus royalties to co-develop TD-4208, Theravance Biopharma's once-daily long-acting muscarinic antagonist (LAMA) delivered by a nebulizer for chronic obstructive pulmonary disease (COPD) and other respiratory diseases.

You may also be interested in...



Theravance Uses Organ-Selective R&D To Advance GI, Pulmonary Candidates

Company develops selective JAK inhibitors for IBD and pulmonary disease that are intended to clear the body before systemic side effects can occur. It also has a drug candidate for NOH that analysts think is underappreciated.

Theravance’s Revefenacin On Track For 2017 Filing With Success In Two Pivotal Trials

Partnered with Mylan to bring the first once-daily nebulized LAMA bronchodilator to market for COPD, Theravance reports statistical significant in two Phase III studies and now awaits data expected next year from an open-label safety study.

Finance Watch: Biopharma IPOs Slow But SPACs Back On The Go

Public Company Edition: It has been almost a month since a biopharma firm launched an IPO in the US, but special purpose acquisition corporations continue to take drug makers public, including Alvotech and Aerami. Outside the US, MaaT closed an IPO in Paris and BeiGene priced a Shanghai offering.

Topics

Related Companies

UsernamePublicRestriction

Register

SC027694

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel